SKYE

Skye Bioscience, Inc. NASDAQ Listed Nov 26, 2014

Healthcare ·Biotechnology ·US · skyebioscience.com

$0.90

Pre-mkt $0.86 -0.31%

Mkt Cap $31.6M

52w Low $0.57 6.4% of range 52w High $5.75

50d MA $0.75 200d MA $1.75

P/E (TTM) -0.6x

EV/EBITDA -0.4x

P/B 1.6x

Debt/Equity 0.0x

ROE -279.3%

P/FCF -0.7x

RSI (14) —

ATR (14) —

Beta 2.87

50d MA $0.75

200d MA $1.75

Avg Volume 564.8K

Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.

SIC Code

2834

CIK (SEC)

1516551

Phone

858 410 0266

11250 El Camino Real · San Diego, CA 92130 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 10, 2026	AMC	-0.30	-0.36	-21.2%	0.80	-17.4%	-9.7%	-2.0%	-6.6%	+8.4%	-6.4%	—
Nov 10, 2025	AMC	-0.33	-0.32	+3.0%	1.42	-1.4%	+2.8%	+4.1%	-9.9%	-5.1%	+7.7%	—
Aug 7, 2025	AMC	-0.34	-0.44	-29.4%	3.55	-1.4%	-0.8%	-0.3%	-7.4%	-3.4%	+4.1%	—
May 8, 2025	AMC	-0.31	-0.28	+9.7%	1.79	+6.1%	+1.1%	+13.3%	-5.4%	-2.1%	+5.8%	—
Mar 20, 2025	AMC	-0.28	-0.24	+14.3%	1.89	+1.1%	+19.0%	+4.4%	+0.4%	-2.5%	-7.8%	—
Nov 7, 2024	AMC	-0.26	-0.22	+15.4%	5.44	+9.6%	+5.0%	-3.7%	-2.0%	-1.5%	+3.8%	—
Aug 9, 2024	AMC	-0.20	-0.20	+0.0%	4.52	-2.7%	+1.8%	-9.8%	+8.4%	+12.0%	-7.5%	—
May 10, 2024	AMC	-0.16	-0.18	-12.5%	11.32	-1.9%	+0.8%	+6.5%	+4.4%	-3.4%	-1.6%	—
Mar 22, 2024	AMC	-0.38	-0.63	-65.8%	12.00	+0.0%	+11.7%	+2.8%	+4.1%	+9.1%	-9.3%	—
Nov 13, 2023	AMC	—	-3.17	—	1.70	+0.0%	-7.1%	-8.9%	+6.2%	+13.7%	-2.9%	—
Aug 7, 2023	AMC	—	-0.80	—	5.25	+4.8%	-9.5%	+0.0%	+0.0%	-10.5%	-5.9%	—
May 11, 2023	AMC	—	-2.50	—	3.75	+0.0%	+0.0%	+6.7%	-6.2%	+0.0%	-6.7%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Jun 24	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$2.87	$3.19	+11.1%	+26.1%	+1.9%	+15.2%	-3.3%	+1.7%
Mar 21	Citizens Capital Markets	Maintains	Market Outperform → Market Outperform	—	$1.89	$1.91	+1.1%	+19.0%	+4.4%	+0.4%	-2.5%	-7.8%
Mar 21	Craig-Hallum	Maintains	Buy → Buy	—	$1.89	$1.91	+1.1%	+19.0%	+4.4%	+0.4%	-2.5%	-7.8%
Sep 20	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$5.49	$3.16	-42.4%	-42.8%	+11.1%	+14.9%	-3.0%	+1.8%
Sep 20	Piper Sandler	Maintains	Overweight → Overweight	—	$5.49	$3.16	-42.4%	-42.8%	+11.1%	+14.9%	-3.0%	+1.8%
Sep 9	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$5.84	$6.00	+2.7%	+8.7%	+10.1%	-9.2%	-5.5%	+0.0%
Sep 6	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$6.06	$6.03	-0.5%	-3.6%	+8.7%	+10.1%	-9.2%	-5.5%
Aug 27	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$6.86	$6.92	+0.9%	-9.6%	-2.1%	+5.3%	-3.1%	-4.8%
Jul 1	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$8.01	$7.23	-9.7%	+0.6%	-6.2%	-1.3%	-26.3%	+11.8%
Jun 18	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$10.86	$10.79	-0.6%	-12.4%	-6.1%	-13.0%	+8.1%	-6.2%
Jun 17	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$10.48	$10.21	-2.6%	+3.6%	-12.4%	-6.1%	-13.0%	+8.1%
Mar 14	Piper Sandler	Maintains	Overweight → Overweight	—	$10.55	$10.20	-3.3%	+22.3%	+2.4%	+2.2%	-2.0%	-4.3%

Data updated apr 27, 2026 1:30am · Source: massive.com